A provider must check insurance, get permission, send a claim the insurer accepts, fight refusals and bill the patient. Waystar's software does those steps.
The company · 2 · What exactly does it sell?
Subscriptions are over half of sales
Each $1 of sales, first half of 2026
54%26%19%2%
Provider subscriptionsFees on patient paymentsFees per claimSet-up and other
The rest is fees per claim or payment, which grow with how many patients providers see.
The company · 3 · How does it make money?
A fee per subscription and per claim
About 97%of revenue kept each year
98%of 2025 revenue from existing clients
43%adjusted profit per $1
Almost no client leaves, so most of each year's revenue is already in place before it starts.
Is it a good business? · 4 · What gives it an edge?
Wired into every link of the billing
About 97%
of revenue kept each year
85%
of contested renewals won
Moving means retesting every link to the record system, bank and insurers while cash keeps coming in.
Epic already sits inside the hospital and needs no new wiring, which undercuts exactly what keeps Waystar's clients. Large systems can also fight refusals with their own staff.
Is it a good business? · 6 · What does its record show?
Profit per $1 widened as sales grew
Sales, $B
0.7
0.8
0.9
1.1
1.3
Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$0.7B → $1.3Bsales, 2022 to the past year
Profit13% → 23%operating profit per $1
Share pay1% → 4%share pay as a part of sales
Share pay and research rose as a share of sales since 2022.
Is it a good business? · 7 · How much room is there to grow?
Providers spend billions fighting refusals
About $19.7Ba year spent fighting denied claims
About 15%of claims to private insurers denied at first
About 5%the market's yearly growth
Waystar's 2025 revenue was about 5.6% of that sum: large, but growing slowly.
Is it a good business? · 8 · Who is in charge?
Buyout firms decide whether to sell
Since 2017Matt Hawkins chief executive
13.0%held by EQT, the largest of four buyout owners
July 2026a new finance chief
Bonuses ride on revenue and adjusted profit; insider sales were almost all under preset plans.
The story right now · 9 · Will AI take Waystar's work?
AI is Waystar's product too
About 40%of new sales were AI tools
EpicAI that drafts appeals
-29%Waystar's shares in a year
AI can read a refusal and draft the appeal. The market fears it lets others do Waystar's job; Waystar sells AI tools of its own.
The story right now · 10 · What makes billing software sticky?
Switching risks a hospital's cash
Software links to everythingRecords, banks, insurers.
Cash flows through itEvery day.
Switching means retestingEvery link, while billing.
So clients stayAbout 97% of revenue kept.
Existing clients' added spending slipped to 107.6% from 108.3%, mostly as a one-off lift from an outage at a rival faded.
The story right now · 11 · What changed lately?
Revenue rose 21% and profit forecasts went up
$325.6Mrevenue, up 21%
43%adjusted profit per $1
+8%fees on claims
About 6%implied fourth-quarter growth
Mixed quarter
The shares fell 29% in a year, and rose 7.1% on a report that the owners are exploring a sale.
The story right now · 12 · What is everyone arguing about?
Does AI shrink this work, or sell more of it?
Many investors think
AI and record vendors will take this work
We think
The work is sticky and growth near today's pace is likely
Against us: Epic already sits inside the hospital. If retention keeps falling, the market is right.
The price and our view · 13 · What is a share worth?
The price sits about a fifth below our value
$35.98what we think a share is worth · the last close is of that
$35.98our value
Attractive below $26.98
Neutral
Unattractive above $43.18
$16.90gloomy: growth halves and less kept per $1
$35.98our estimate: experts' path, then slowing
$48.55sunny: growth runs faster
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
Epic, floating-rate debt and a sale
Epic does it insideBiggest
No second vendor needed.
A sale on owners' termsShowing now
Bankers reportedly hired.
Another breachWatch
Source code taken in June.
Where retention settlesUnknown
After outage clients count.
About $1.28B of debt pays interest that rises with rates, and patient visits grow only 1% to 2% a year.
The price and our view · 15 · How will we know?
February brings the 2027 forecast
Growth, leaving out the Iodine purchase, near 8% to 10%Good sign
Clients' added spending steady near 108%Good sign
Growth under 7%, or that figure under 107%Bad sign
FEB 202716
Fourth-quarter 2026 results and 2027 forecast, 16 February. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: we turn positive if the shares fall a quarter below our estimate, and negative a fifth above it.
The price and our view · 16 · So, what do we think?
The pipes hospitals bill through, fairly priced
$35.98our value
Attractive below $26.98
Neutral
Unattractive above $43.18
NeutralMedium conviction
Waystar's software checks, sends and chases payment for about 30,000 healthcare providers, and almost none leave. The price pays for growth near today's pace, with Epic the main threat. Neutral.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
A hospital does not get paid when it treats you. It has to check your insurance, sometimes get permission first, send a claim the insurer will accept, fight it if it is denied, and then bill you for what is left. Each step fails often and costs staff time.
Waystar sells cloud software that does those steps, for about 30,000 providers and 7.5 billion transactions a year. The alternatives are other billing vendors, the hospital's own record system, or people doing it by hand.
How it makes money
Two ways. Providers pay a subscription for the software, and Waystar charges a fee on each claim or patient payment that runs through it. Over 99% of revenue is one or the other, on contracts of two to three years that then renew each year with price rises.
The patient payments fees look large but card and bank costs eat about 60% of them, so the subscription and claims work is where the profit sits.
Growth and profit
What growth costs
Growth is not getting cheaper to buy in one way: stock pay, research and capitalised software have all risen as a share of sales since 2022, while selling costs held flat. Margins still widened, because the extra revenue costs little to serve, but more of the profit now goes to staff in shares.
Its record
The numbers
Is it growing?Steady
Sales grew 21% over the twelve months to Sep 2026, about the same pace as the 17% in the year to Dec 2025.
Is it profitable?Strong
Operating margin is 22%, up from 18% in the year to Dec 2023.
How steady is it?Steady
Yearly sales growth has ranged from +12% to +19% over the last 3 years.
Does it earn good returns?Low
Each dollar put into the business earns 3.9% a year after tax, about where it was (3.4%) in the year to Dec 2025.
Is it making cash?Strong
It turned 21% of sales into free cash, $264M over the last twelve months.
Is the balance sheet safe?Heavy debt
It owes $1.19B more than the cash it holds, about 3.8 years of the cash its operations bring in.
Are shares being diluted?Diluting
The share count rose 61% in 3.8 years, and pay in shares costs 4.9% of sales.
Why it wins
The evidence
Once a hospital's billing runs through Waystar, it is wired into the record system, the bank and hundreds of insurers. Moving means re-testing every link while the cash keeps coming in, so few try.
The numbers bear it out. Management says about 97% of revenue is kept each year, 98% of 2025 revenue came from clients signed before it began, and when a client did shop around from 2023 to 2025, Waystar won 85% of the time.
Who could beat it
The rivals in full
The rival that matters is Epic, the private company whose records most large hospitals run on. Its AI tool Penny already cuts coding denials and drafts appeal letters, and Epic says it will later file appeals itself. Optum, inside UnitedHealth, sells the same kind of software through Change Healthcare. Epic needs no new wiring, which is exactly Waystar's moat.
Each rival
Epic Systems (Penny revenue cycle AI)private
Denial prevention, coding checks and appeal letters, built into the health record most large hospitals already run.
Optum Insight (Change Healthcare)UNH
The clearinghouse and revenue cycle tools, now running again after the 2024 outage that sent providers to Waystar.
Experian HealthEXPN.L
Eligibility checks, patient access and claims tools, sold inside a credit bureau.
Revenue cycle tools sold with the Cerner health record.
Availity, FinThrive, R1 RCM and athenahealthprivate
Clearinghouse, claims and outsourced billing work from privately owned rivals.
Health systems' own billing staff and systemsin house
Claims and denials worked by hand or on tools a large system builds itself.
How big it could get
The market and who has signed
The market
Insurers turn down about one claim in seven at first, and providers spend about $19.7B a year fighting them, by Premier's count from a survey of 516 hospitals. Federal data show the same picture on HealthCare.gov plans, where a fifth of claims were denied.
Waystar's 2025 revenue was about 5.6% of that sum. Management puts its whole market at $20B, growing about 5% a year: large, but growing slowly.
Who runs it
Leaders, pay and the cash
Who runs it
Matt Hawkins has run Waystar since 2017, through its private-equity years and its 2024 listing; he owns about 1.9%. The buyout firms that own about a third, led by EQT, each name a director, so they decide whether to sell.
Executive bonuses ride on revenue and adjusted profit, and the chief executive's share awards on how the shares do against peers. Insider sales in the last year were almost all under plans set in advance. A new finance chief arrived in July 2026.
What they did with the money
The big move was buying Iodine, AI software that reads clinical notes, for $1.26B, part in cash and part in new shares, which raised the share count 7%. In May the board approved a $200M buyback, and Waystar bought shares near $19 in the second quarter.
The last report
The latest report
Waystar's Q3 2026 revenue rose 21% to $325.6M, with profit forecasts raised
What it did to the thesis Mixed quarter
It left the view where it was. Growth without Iodine met our line, which helps, but the forecast implies a slower fourth quarter and client spending sat just under our marker.
The report
Revenue rose 21% to $325.6M in the third quarter, with an adjusted profit margin of 43%. Fees on claims grew 8%, up from under 3%, and the company raised its 2026 profit forecasts while narrowing its sales range. On the call it said growth without Iodine was 10%.
The forecast implies fourth-quarter sales growth of only about 6%. Management blames three things worth about 4 points: patients moving from printed to digital statements, a later start to revenue from an Iodine product that is paid by results, and a tough comparison with three fast client launches a year ago. Existing clients' added spending slipped to 107.6% from 108.3% in June.
What's happening now
The background
The shares are 29% lower than a year ago after falling sharply on both 2026 prints, then rose 7.1% when Reuters reported in September that Waystar was exploring a sale.
Q3 2026 results came out on 2 November with growth without Iodine at 10% and fees on claims up 8%. Management says 2026 is a year of selling new AI products, with the revenue showing in 2027. The forecast implies a slower fourth quarter, so the next test is whether growth holds near 10%.
Where we disagree
Both sides in full
The market
AI and the record vendors will take this work, so slowing growth is the start of a decline.
We believe
The work is sticky and AI is also Waystar's product; growth near today's pace is likely, and the price already pays for it.
The argument
Buyers sold both 2026 prints on falling retention, but the fall is mostly the outage lift fading: the clients stayed. AI tools were about 40% of new bookings this year.
The evidence against us is real. Epic sits inside the hospital already, and a vendor that needs no new wiring weakens the very reason clients stay. If retention keeps falling after the outage clients are fully counted, the market is right.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
What the price assumes
Sales growth in the first year, then slowing as ours does, at the same profit per sale.
The price assumed
4.6%
Our estimate
9%
Measured at the close of
12 Nov 2026
The three cases
Bear case$16.90
Growth runs at half the analysts' path, 5%, 5% and 4%, the margin settles a fifth lower at 30.2%, and new capital earns only the 8% rate: the downturn test.
Our value$35.98
Revenue grows 9%, 11% and 9% over three years, the analysts' path (C45), then fades toward 4%, closing 30% of the gap each year; the margin moves to 37.8%, the analysts' year-three figure after stock pay and on the filed basis (2.1% less).
Bull case$48.55
Growth runs a quarter above the analysts' path, 12%, 13% and 11%, the margin reaches 41.6%, and new capital earns 15%.
What could go wrong
Every risk
The risks
Epic does it inside
Hospitals on Epic can file and appeal claims without a second vendor, and Epic says its AI will soon submit appeals on its own.
Debt on a floating rate
Net debt is about $1.28B, mostly a loan due 2029 whose interest moves with short-term rates.
A sale on the owners' terms
Buyout firms own about a third and have reportedly hired bankers; a sale could come at a price that suits them, not later buyers.
Slow patient volumes
Patient visits grow 1% to 2% a year, so fee growth depends on winning clients and selling more to them.
Another breach
Intruders took source code and some health data from a supplier's storage in June 2026; a worse one would test the trust that keeps clients.
What we still do not know
Where net retention settles once the clients won after the 2024 outage are fully counted: management's target is 108% to 110%.
Whether the AI products sold in 2026 show up as revenue growth in 2027, as management says.
Whether growth without purchases returns to the 10% or more management targets, or settles nearer 7%.
What changes our view
Every route to a new view
Every route to a new view
→ Attractive
The share price falls to about $26.99, 75% of what we think the business is worth.
→ Unattractive
The share price rises to about $43.18, 20% above what we think the business is worth.
The next test
It supports the case if
Organic growth of 8% or more, volume revenue growing at 5% or more from a year earlier, net retention at or above 108% and 2027 guidance near low double digits.
It pressures the case if
Organic growth below 7%, net retention below 107%, or 2027 revenue guided below 8% growth.
We would also be wrong if
Growth without purchases below 6% for two quarters in a row.
Net retention below 106% over twelve months.
A large health system moves its claims work to Epic, and Waystar names it.
The verdict
Scores and how we weighed it
The scores
Growth
3 of 4
Business quality
3 of 4
Financial position
3 of 4
Execution record
3 of 4
Per share capture
3 of 4
Potential
2 of 4
Risk profile
3 of 4
Valuation
3 of 4
Evidence quality
3 of 4
How we weighed it
ValueMixed
The price has slipped just past the line where the margin of safety begins, on no news; the cushion is thin and the bear case sits far below.
BusinessPositive
Hospitals and clinics bill through it every day, almost none leave, and it keeps a wide margin.
GrowthMixed
The price pays for modest growth for ever, about what the business manages without purchases.
RisksNegative
A large rival builds billing into its own software, debt floats with rates, buyout owners may exit on their terms and a supplier was breached.
RivalsNegative
The largest hospital software maker does the same work inside its own product.
The groupMixed
It sits in none of our ranked groups; patient volumes and hospital budgets move it.
Latest newsMixed
The last report met our growth line, but the forecast implies a slower quarter ahead.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.